en · de · es · fr · pt
peptide-index.peptides1004.com › Guide › Receptor Selectivity And Secretagogue Signaling — Reference Sheet

Receptor Selectivity And Secretagogue Signaling — Reference Sheet

By Editorial Desk · published 2026-03-22 · last reviewed 2026-04-24 · Guide

Everything below concerns ghrelin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Receptor Selectivity and Secretagogue Signaling

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Background and Receptor Selectivity

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Reported for the free peptide
Molecular mass711.85 DaMonoisotopic value
Residue motifAib-His-D-2-Nal-D-Phe-Lys-NH2Non-natural residues at positions one and three
Primary targetGHSR-1aGhrelin receptor, G protein coupled
Reported plasma half-lifeAbout two hoursValues vary with assay and subject group

Background And Receptor Mechanism

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Related pages on this site

Handling, Storage, and Analytics

Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.

Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.

Receptor Mechanism and Secretagogue Action

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

Background from the literature

== Media image == Larter first appeared in the media when she portrayed the fictional character of Allegra Coleman in the November 1996 issue of Esquire. The magazine, which billed Coleman as the movies' next dream girl, relayed Allegra's relationship with David Schwimmer, how Quentin Tarantino broke up with Mira Sorvino to date her, and Woody Allen then overhauled a film to give her a starring role. When the magazine was published, Esquire received hundreds of phone calls about the non-existent Coleman and various talent agencies sought to represent her, even after the hoax was revealed. Larter herself received a considerable amount of attention after the cover; she received phone calls from morning TV shows and others for interviews. The Esquire cover led Larter to a role on Varsity Blues. One particular scene where Larter's character, Darcy Sears, wears nothing but whipped cream to cover herself has become a media favorite. It has been referenced many times in the media including on MTV's Jersey Shore, where a character refers to it as being the "Varsity Blues outfit". Larter has been acknowledged as a scream queen by MSN due to her appearances in horror/thriller films. After the success of Heroes, she appeared on People's "Ten Best Dressed List" as "The Newcomer" in 2007. In 2009, she was named Cosmopolitan's Fun Fearless Female of the year at a ceremony held in Beverly Hills, California.

== Clinical significance == Mutations in the COL3A1 gene cause vascular Ehlers-Danlos syndrome (vEDS; OMIM 130050), classified under this name in the 2017 International Classification of the Ehlers–Danlos Syndromes and formerly designated EDS type IV. It is the most severe form of EDS, since patients often die suddenly due to rupture of large arteries or other hollow organs. A few patients with arterial aneurysms without clear signs of EDS have also been found to have COL3A1 mutations. More recently, mutations in COL3A1 have also been identified in patients with severe brain anomalies suggesting that type III collagen is important for the normal development of the brain during embryogenesis. This phenotype resembles the cortical malformation caused by loss-of-function mutations in ADGRG1 (formerly GPR56; OMIM 604110), the gene encoding adhesion G protein-coupled receptor G1. Type III collagen is a known ligand for this receptor, linking the finding to a shared brain-development pathway. The first single base mutation in the COL3A1 gene was reported in 1989 in a patient with vEDS and changed a glycine amino acid to a serine Since then, more than 600 different variants have been reported in the COL3A1 gene. About 2/3 of these mutations change a glycine amino acid to another amino acid in the triple-helical region of the protein chain. A large number of RNA splicing mutations have also been identified.

=== Appearance === Natural casing sausages are distinguishable from collagen or cellulose casings because of their irregularity, although high-quality sheep and lamb casings can be almost indistinguishable from a collagen casing as they have no noticeable imperfections. The main difference is in the way they are twisted and linked which affects the appearance of the final product and makes it easy to differentiate a hot dog using natural sheep or lamb casing vs collagen casing. The size and usage of natural casings relate to the animal from which they are derived, the narrowest being lamb followed by sheep followed by pig followed by beef. The size range for lamb is 14 mm to 28 mm in diameter (which is how casings are graded), the size range for sheep is 16 mm to 32 mm in diameter, the size range for pig is 28 mm to 58 mm in diameter, the size range for beef is 43 mm to 65 mm, although beef bung caps (which are not derived from the small intestine) have a size range of 115 mm to 130 mm.

Marfan syndrome - inherited as an autosomal dominant characteristic, due to mutations in the FBN1 gene that encodes fibrillin 1. Homocystinuria - condition of methionine metabolism brought on by a cystathionine β-synthase deficit that causes a build-up of homocysteine and its metabolites in the urine and blood. Ehlers–Danlos syndrome - diverse collection of disorders distinguished by the fragility of soft connective tissues and widespread symptoms affecting the skin, ligaments, joints, blood vessels, and internal organs. Osteogenesis imperfecta - hereditary condition marked by reduced bone mass, weakened bones, increased brittleness, and short stature. Alkaptonuria - inborn error of metabolism caused by mutations in the HGO gene and homogentisate 1,2-dioxygenase deficiency. Pseudoxanthoma elasticum - rare multisystem disease marked by gradual calcification and fragmentation of elastic fibres. Mucopolysaccharidosis - a class of hereditary illnesses distinguished by the excretion of mucopolysaccharide in the urine. Fibrodysplasia ossificans progressiva - rare and debilitating hereditary disorder characterized by progressive heterotopic ossification and congenital skeletal malformations. Familial osteochondritis dissecans - separation of the subchondral bone and cartilage from the surrounding tissue. Stickler syndrome - autosomal dominant disorder distinguished by skeletal, ocular, and orofacial abnormalities.

Collagen, type I, alpha 1, also known as alpha-1 type I collagen, is a protein that in humans is encoded by the COL1A1 gene. COL1A1 encodes the major component of type I collagen, the fibrillar collagen found in most connective tissues, including cartilage.

Sources: en.wikipedia.org

Reference notes

==== Injection stabilizer ==== Gelatin also acts as a stabilizer in vaccines and other injected drugs, helping the mixture stay uniform to maintain effect and consistency. Unfortunately a small portion of the population is allergic to gelatin, leading to a potentially severe systemic reaction when injected. This has led to its voluntary phase-out from vaccines in a number of countries such as Japan.

Upon further compression to 23 GPa, americium transforms to an orthorhombic γ-Am structure similar to that of α-uranium. There are no further transitions observed up to 52 GPa, except for an appearance of a monoclinic phase at pressures between 10 and 15 GPa. There is no consistency on the status of this phase in the literature, which also sometimes lists the α, β and γ phases as I, II and III. The β-γ transition is accompanied by a 6% decrease in the crystal volume; although theory also predicts a significant volume change for the α-β transition, it is not observed experimentally. The pressure of the α-β transition decreases with increasing temperature, and when α-americium is heated at ambient pressure, at 770 °C it changes into an fcc phase which is different from β-Am, and at 1075 °C it converts to a body-centered cubic structure. The pressure-temperature phase diagram of americium is thus rather similar to those of lanthanum, praseodymium and neodymium. As with many other actinides, self-damage of the crystal structure due to alpha-particle irradiation is intrinsic to americium. It is especially noticeable at low temperatures, where the mobility of the produced structure defects is relatively low, by broadening of X-ray diffraction peaks. This effect makes somewhat uncertain the temperature of americium and some of its properties, such as electrical resistivity. So for americium-241, the resistivity at 4.2 K increases with time from about 2 μOhm·cm to 10 μOhm·cm after 40 hours, and saturates at about 16 μOhm·cm after 140 hours.

An ancient text known as The Yellow Emperor's Classic of Internal Medicine identifies the brain as the nexus of wisdom and sensation, includes theories of personality based on yin–yang balance, and analyzes mental disorder in terms of physiological and social disequilibria. Chinese scholarship that focused on the brain advanced during the Qing Dynasty with the work of Western-educated Fang Yizhi (1611–1671), Liu Zhi (1660–1730), and Wang Qingren (1768–1831). Wang Qingren emphasized the importance of the brain as the center of the nervous system, linked mental disorder with brain diseases, investigated the causes of dreams, insomnia, psychosis, depression and epilepsy.

=== Elder welfare === In 2004, Ambani established Harmony for Silvers Foundation, a Mumbai-based non-government organisation that seeks to enhance the quality of life of the elderly. Its activities have included Harmony – Celebrate Age, the magazine, now in its 14th year; the portal www.harmonyindia.org; Harmony Interactive Centre for Silver Citizens, in South Mumbai; the Harmony Research Division; the Harmony Silver Awards; and the Harmony Senior Citizens' Runs at the Mumbai, Delhi and Bengaluru marathons.

Sources: en.wikipedia.org

Frequently asked questions

How does ipamorelin relate to ghrelin?

Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.

Why is it described as selective?

Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.

What is known about its metabolism?

Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.

Is ipamorelin an approved medicine?

It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.

Network